Self-Nanoemulsifying Drug Delivery System for Atorvastatin Calcium: Design, Optimization and Evaluation
Abstract
Atorvastatin calcium (ATC) is the choice of drug in the treatment of moderate to severe hypercholesterolemia. In the current study, ATC self-nanoemulsifying drug delivery systems (SNEDDS) were prepared in an attempt to improve the bioavailability by enhancing its solubility. The solubility of ATC in various oils, surfactants, and co-surfactants were determined. Based on their solubility, Capmul MCM (oil), Tween 20 (surfactant), propylene glycol (Co-surfactant) was selected for preparation of SNEDDS. Self-nanoemulsification region were determined by pseudo-ternary phase diagrams. The compatibility of drug with excipients were determined by FTIR spectroscopy and Optimized SNEDDS were evaluated for thermodynamic stability, dispersibility, robustness to dilution, particle size measurements, refractive index, percent transmittance, drug content, In vitro drug release etc. The SNEDDS were successfully formulated with the selected excipients. FTIR studies confirm there is no significant interaction between drug and excipients. The metastable formulations were ruled out by thermodynamic tests and robust to dilution test. The optimized ATC SNEDDS yielded nano-emulsion of mean globule size 42.21 nm. In vitro release studies shows that all the SNEDDS released more than 90% of drug at the end of 30 min, whereas the pure drug shows only the release of 29.54% at 30 min. The optimized formulation was subjected to various conditions of storage as per ICH guidelines for 3 months. ATC SNEDDS successfully withstood the stability testing. Thus this study indicates that the SNEDDS can be used as a potential drug carrier for solubility enhancement thereby drug release of ATC and other lipophilic drugs.
Keywords: Self-nanoemulsifying drug delivery systems, Pseudo-ternary phase diagrams, Thermodynamic stability
Cite this Article
Panner Selvam R, Parthasarathi K Kulkarni, Mudit Dixit, Self-Nanoemulsifying Drug Delivery System for Atorvastatin Calcium: Design, Optimization and Evaluation, Research & Reviews: A Journal of Drug Design & Discovery, 2015; 2(2): 27–36p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
